Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

卷:84

Article

Paller, Amy S.¹  Gold, Linda Stein²  Soung, Jennifer³  Tallman, Anna M.⁴  Rubenstein, David S.⁵  Gooderham, Melinda^6,7 

[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[2] Henry Ford Hlth Syst, Detroit, MI USA

[3] Southern Calif Dermatol, Santa Ana, CA USA

[4] Dermavant Sci Inc, Long Beach, CA USA

[5] Dermavant Sci Inc, Durham, NC USA

[6] SKiN Ctr Dermatol, Prob Med Res, Peterborough, ON, Canada

[7] Queens Univ, Peterborough, ON, Canada

关键词: atopic dermatitis;    patient-reported outcomes;    tapinarof;    therapeutic aryl hydrocarbon receptor (AhR) modulating agent (TAMA);    topical therapy;   

DOI  :  10.1016/j.jaad.2020.05.135

来源: Elsevier

【 摘 要 】

Background: Tapinarof is a topical therapeutic aryl hydrocarbon receptor modulating agent under investigation for atopic dermatitis (AD) and psoriasis treatment. Methods: A phase 2b, double-blind, vehicle-controlled study randomly assigned adolescents and adults with AD to receive tapinarof cream 0.5%, 1%, or vehicle, once or twice daily, for 12 weeks with a 4-week follow-up. Outcomes included Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI), body surface area affected, pruritus numeric rating scale scores, patients' impressions of AD and pruritus symptom severity, and Patient-Oriented Eczema Measure (POEM) scores. Results: Overall, 191 of 247 randomized patients completed the study. Week 12 IGA responses were higher in the tapinarof groups versus the vehicle group, reaching statistical significance with tapinarof 1% twice daily, >= 75%/90% improvement in EASI from baseline were significantly higher in the tapinarof groups (except 0.5% once daily and 0.5% twice daily), EASI scores were significantly improved in all tapinarof groups, and body surface area affected was significantly reduced in the tapinarof groups (except 0.5% twice daily). More patients reported AD and pruritus symptom severity as very/moderately improved in tapinarof groups, and POEM improvements were observed in all groups. Most adverse events were mild or moderate. Limitations: Larger prospective studies are required to confirm the reported analyses. Conclusions: Tapinarof is a potential important advance in topical medicine development for AD.

【 授权许可】

Free